Literature DB >> 3126410

Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures.

P Gal1, K S Oles, J T Gilman, R Weaver.   

Abstract

Six neonates with prolonged, intractable seizures were treated with valproic acid (VPA). Each patient had received maximum doses of phenobarbital (greater than 40 micrograms/ml), and five patients received at least two additional anticonvulsants, without success. Seizure activity was controlled in five of six (83%) cases. In four cases, all other anticonvulsants could be withdrawn, and seizures were controlled on VPA monotherapy. VPA was discontinued in three patients because of VPA-induced hyperammonemia. VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg). T1/2 = 17.6 hours (6.7 to 34.2). VPA free fraction ranged from 11.3 to 31.6% (mean, 19.2%).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126410     DOI: 10.1212/wnl.38.3.467

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients.

Authors:  Jason H Williams; Bhuvaneswari Jayaraman; Kathryn J Swoboda; Jeffrey S Barrett
Journal:  J Clin Pharmacol       Date:  2011-12-13       Impact factor: 3.126

Review 2.  Neonatal seizures.

Authors:  D Evans; M Levene
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-01       Impact factor: 5.747

Review 3.  Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report.

Authors:  Pavla Pokorná; Karolina Hronová; Martin Šíma; Ondřej Slanař; Petr Klement; John N van den Anker; Dick Tibboel
Journal:  Eur J Clin Pharmacol       Date:  2017-02-06       Impact factor: 2.953

Review 4.  The clinical conundrum of neonatal seizures.

Authors:  M Levene
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-03       Impact factor: 5.747

5.  2-Ethylhexanoic acid inhibits urea synthesis and stimulates carnitine acetyltransferase activity in rat liver mitochondria.

Authors:  A Manninen; S Kröger; J Liesivuori; H Savolainen
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

6.  Neonatal Seizures.

Authors:  Michael J. Painter; John Alvin
Journal:  Curr Treat Options Neurol       Date:  2001-05       Impact factor: 3.598

7.  Evaluation of workers' exposure to 2-ethylhexanoic acid (2-EHA) in Finnish sawmills. A field study.

Authors:  S Kröger; J Liesivuori; A Manninen
Journal:  Int Arch Occup Environ Health       Date:  1990       Impact factor: 3.015

Review 8.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

9.  A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures.

Authors:  Joanie K Tulloch; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

10.  Etiology of neonatal seizures and maintenance therapy use: a 10-year retrospective study at Toulouse Children's hospital.

Authors:  E Baudou; C Cances; C Dimeglio; C Hachon Lecamus
Journal:  BMC Pediatr       Date:  2019-04-29       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.